Search - tctmd.com

Displaying 281 - 300 of 440

Sort: Relevancy | Date

News Conference News TCT 2012

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

October 24, 2012

Presentation TCT 2012

TCT-70. Comparison of Efficacy and Safety Between Sirolimus, Paclitaxel, Everolimus-eluting Stent and SeQuent™ Please, a Drug-eluting Balloon on the Outcome of Patients with...

Presenter: Sunao Nakamura

October 23, 2012

Presentation TCT 2012

TCT-48. Two Year Follow-up and Sub-group Analysis of a Polymer-free Sirolimus- and Probucol-eluting Stent vs. A New Generation Zotarolimus-eluting Stent in Coronary Artery Disease

Presenter: Lamin King

October 23, 2012

Presentation TCT 2012

TCT-44. LEADERS: 5-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable...

Presenter: Patrick Serruys

October 23, 2012

Presentation TCT 2012

TCT-41. The Impact of Left Main Disease on Long-term Clinical Outcomes Among Patients Treated with the Unrestricted Use of Everolimus-Eluting, Sirolimus-Eluting, and...

Presenter: Giulio Stefanini

October 23, 2012

Presentation TCT 2012

TARGET I: A Prospective, Randomized Trial of a Biodegradable Polymer-based Sirolimus-Eluting Stent vs an Everolimus-Eluting Stent (MicroPort)

Presenter: Run-Lin Gao

October 23, 2012

Presentation TCT 2012

Sirolimus-Eluting Stent (Svelte Medical) Program Update

Presenter: Mark Webster

October 23, 2012

News Industry News

Micell Technologies Announces Positive Data from Clinical Studies of MiStent SES

October 23, 2012

News Conference News TCT 2012

Large Study Finds Comparable 8-Month TVF for PES, SES

October 23, 2012

Presentation TCT 2012

DESSOLVE II: A Prospective, Randomized Trial of a Biodegradable Polymer-based Sirolimus-Eluting Stent vs a Zotarolimus-Eluting Stent (Micell)

Presenter: David Kandzari

October 23, 2012

News Conference News TCT 2012

Several Trials Highlight DES Comparisons

October 22, 2012

News Conference News TCT 2012

Meta-Analyses Show Improved Outcomes with DES vs. BMS

October 22, 2012

Presentation TCT 2012

J-DESSERT: A Prospective, Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents in Patients with and without Diabetes

Presenter: Masato Nakamura

October 22, 2012

News Industry News

OrbusNeich’s COMBO Dual Therapy Stent™ to be Featured in Multiple Clinical Data Presentations Next Week at TCT 2012(2)

October 16, 2012

News Industry News

OrbusNeich’s COMBO Dual Therapy Stent™ to be Featured in Multiple Clinical Data Presentations Next Week at TCT 2012

October 16, 2012

News Daily News

Stent Fractures Persist Among Newer-Generation Devices

Jason Kahn

October 02, 2012

News Daily News

Las Fracturas del Stent Persisten en los Dispositivos de Nueva Generación

Jason Kahn

October 02, 2012

News Daily News

SORT OUT IV: Xience Holds Edge Over Cypher for Preventing Stent Thrombosis

Yael L. Maxwell

September 07, 2012

News Daily News

SORT OUT IV: El Xience Aguanta el Tirón del Cypher en la Prevención de la Trombosis del Stent

Yael L. Maxwell

September 07, 2012

News Conference News ESC 2012

ESC Congress 2012: Diverse Lineup of Practice-Changing Presentations

Caitlin E. Cox

September 04, 2012

Advertisement

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

TCT-70. Comparison of Efficacy and Safety Between Sirolimus, Paclitaxel, Everolimus-eluting Stent and SeQuent™ Please, a Drug-eluting Balloon on the Outcome of Patients with...

TCT-48. Two Year Follow-up and Sub-group Analysis of a Polymer-free Sirolimus- and Probucol-eluting Stent vs. A New Generation Zotarolimus-eluting Stent in Coronary Artery Disease

TCT-44. LEADERS: 5-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable...

TCT-41. The Impact of Left Main Disease on Long-term Clinical Outcomes Among Patients Treated with the Unrestricted Use of Everolimus-Eluting, Sirolimus-Eluting, and...

TARGET I: A Prospective, Randomized Trial of a Biodegradable Polymer-based Sirolimus-Eluting Stent vs an Everolimus-Eluting Stent (MicroPort)

Sirolimus-Eluting Stent (Svelte Medical) Program Update

Micell Technologies Announces Positive Data from Clinical Studies of MiStent SES

Large Study Finds Comparable 8-Month TVF for PES, SES

DESSOLVE II: A Prospective, Randomized Trial of a Biodegradable Polymer-based Sirolimus-Eluting Stent vs a Zotarolimus-Eluting Stent (Micell)

Several Trials Highlight DES Comparisons

Meta-Analyses Show Improved Outcomes with DES vs. BMS

J-DESSERT: A Prospective, Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents in Patients with and without Diabetes

OrbusNeich’s COMBO Dual Therapy Stent™ to be Featured in Multiple Clinical Data Presentations Next Week at TCT 2012(2)

OrbusNeich’s COMBO Dual Therapy Stent™ to be Featured in Multiple Clinical Data Presentations Next Week at TCT 2012

Stent Fractures Persist Among Newer-Generation Devices

Las Fracturas del Stent Persisten en los Dispositivos de Nueva Generación

SORT OUT IV: Xience Holds Edge Over Cypher for Preventing Stent Thrombosis

SORT OUT IV: El Xience Aguanta el Tirón del Cypher en la Prevención de la Trombosis del Stent

ESC Congress 2012: Diverse Lineup of Practice-Changing Presentations

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content